Atypical Antipsychotic Use in a State Hospital Inpatient Adolescent Population

Journal of Child and Adolescent Psychopharmacology

Volumn 14, Issue 1, 2004, Pages 75-85

  Kelly, Deanna L ^a,c   Love, Raymond C ^b   Mackowick, Marie ^b   McMahon, Robert P ^a   Conley, Robert R ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADOLESCENCE; ADOLESCENT; ADULT; ARTICLE; DRUG USE; FEMALE; HOSPITAL; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POPULATION; PRESCRIPTION; PSYCHOSIS;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHI-SQUARE DISTRIBUTION; CHILD; FEMALE; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; HOSPITALS, STATE; HUMANS; MALE; MENTAL DISORDERS; RETROSPECTIVE STUDIES;

EID: 1942507356     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454604773840517     Document Type: Article

References (60)

1. Armenteros JL, Whitaker AH, Welikson M, Stedge DJ, Gorman J: Risperidone in adolescents with schizophrenia: An open pilot study. J Am Acad Child Adolesc Psychiatry 36:694-700, 1997.
2. Baptista T, Teneud L, Contreras Q, Alastre T, Burguera JL, de Burguera M, de Baptista E, Weiss S, Hernandez L: Lithium and body weight gain. Pharmacopsychiatry 28:35-44, 1995.
3. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S: Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123, 1996.
4. Birmaher B, Baker R, Kapur S, Quintana H, Ganguli R: Clozapine for the treatment of adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 31:160-164, 1992.
5. Bray GA, Davidson MB, Drenick EJ: Obesity: A serious symptom. Ann Intern Med 77:779-795, 1972.
6. Bryden KE, Carrey NJ, Kutcher SP: Update and recommendations for the use of antipsychotics in early-onset psychoses. J Child Adolesc Psychopharmacol 11:113-130, 2001.
7. Buitelaar JK: Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol 10:19-26, 2000.
8. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT: A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62:239-248, 2001.
9. Chang KD, Ketter TA: Mood stabilizer augmentation with olanzapine in acutely manic children. J Child Adolesc Psychopharmacol 10:45-49, 2000.
10. Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R, Pietrosante M, Salvatore M, Lombardi G: Prolactinomas in adolescents: Persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) 52:319-327, 2000.
11. Daniels S: Pharmacological treatment of obesity in paediatric patients. Paediatr Drugs 3:405-410, 2001.
12. Demir E, Aysun S: Weight gain associated with valproate in childhood. Pediatr Neurol 22:361-364, 2000.
13. Depres JP, Moorjani S, Lupien PJ, Tremblay A, Naudeau A, Bouchard C: Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 10:497-511, 1990.
14. Dickson RA, Glazer WM: Neuroleptic-induced hyperprolactinemia. Schizophr Res 35:S75-S86, 1999.
15. Duntas LH: Prolactinomas in children and adolescents - Consequences in adult life. J Pediatr Endocrinol Metab 14(Suppl 5):1227-1232, 2001.
16. Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J: Risperidone in treating behavioral disturbances of Prader-Willi syndrome. Acta Psychiatr Scand 102:461-465, 2000.
17. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL: A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509-516, 2000a.
18. Findling RL, McNamara NK, Gracious BL: Paediatric uses of atypical antipsychotics. Expert Opin Pharmacother 1:935-945, 2000b.
19. Fisman S, Steele M, Pipher B: Risperidone in PDD. J Am Acad Child Adolesc Psychiatry 37:15-16, 1998.
20. Fitzgerald KD, Stewart CM, Tawile V, Rosenberg DR: Risperidone augmentation of serotonin re-uptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharmacol 9:115-123, 1999.
21. Frazier JA, Biederman J, Tohen M, Feldman PD, Jacobs TG, Toma V, Rater MA, Tarazi RA, Kim GS, Garfield SB, Sohma M, Gonzalez-Heydrich J, Risser RC, Nowlin ZM: A prospective open label treatment of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 11:239-250, 2001.
22. Frazier JA, Gordon CT, McKenna K, Lenane MC, Jih D, Rapoport JL: An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 33: 658-663, 1994.
23. Frazier JA, Meyer MC, Biederman J, Wozniak J, Wilens TE, Spencer TJ, Kim GS, Shapiro S: Risperidone treatment for juvenile bipolar disorder: A retrospective chart review. J Am Acad Child Adolesc Psychiatry 38:960-965, 1999.
24. Guo SS, Roche AF, Chumlea WC, Gardner JD, Siervogel RM: The predictive value of childhood body mass index values for overweight at age 35 y. Am J Clin Nutr 59:810-819, 1994.
25. Gupta S, Frank B, Madhusoodanan S: Risperidone-associated galactorrhea in a male teenager. J Am Acad Child Adolesc Psychiatry 40:504-505, 2001.
26. Hanna GL, Fluent TE, Fischer DJ: Separation anxiety in children and adolescents treated with risperidone. J Child Adolesc Psychopharmacol 9:277-283, 1999.
27. Hoffmans MD, Kromhout D, Coulander CD: Body mass index at the age of 18 and its effects on 32-year-mortality from coronary heart disease and cancer. A nested case-control study among the entire 1932 Dutch male birth cohort. J Clin Epidemiol 42:513-520, 1989.
28. Jensen PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke LB: Psychoactive medication prescribing practices for U.S. children: Gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry 38:557-565, 1999.
29. Jureidini JN: Epidemic of schizophrenia in children or inappropriate prescribing? Med J Aust 173: 555-556, 2000.
30. Kaplan SL, Busner J: Prescribing practices of inpatient child psychiatrists under three auspices of care. J Child Adolesc Psychopharmacol 7: 275-286, 1997.
31. Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM: Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 8:151-159, 1998.
32. Kewley GD: Risperidone in comorbid ADHD and ODD/CD. J Am Acad Child Adolesc Psychiatry 38:1327-1328, 1999.
33. Kowatch RA, Suppes T, Gilfillan SK, Fuentes RM, Grannemann BD, Emslie GJ: Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: A clinical case series. J Child Adolesc Psychopharmacol 5:241-253, 1995.
34. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, Hamburger SD, Smith AK, Albus KE, Alaghband-Rad J, Rapoport JL: Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 53:1090-1097, 1996.
35. Kumra S, Jacobsen LK, Lenane M, Karp BI, Frazier JA, Smith AK, Bedwell J, Lee P, Malanga CJ, Hamburger S, Rapoport JL: Childhood-onset schizophrenia: An open-labeled study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 37:377-385, 1998.
36. Maffeis C, Tato L: Long-term effects of childhood obesity on morbidity and mortality. Horm Res 55(Suppl 1):42-45, 2001.
37. Malone RP, Sheikh R, Zito JM: Novel antipsychotic medications in the treatment of children and adolescents. Psychiatr Serv 50:171-174, 1999.
38. Martin A, Landau J, Leebens P, Ulizio K, Cicchetti D, Scahill L, Leckman JF: Risperidone-associated weight gain in children and adolescents: A retrospective chart review. J Child Adolesc Psychopharmacol 10:259-268, 2000.
39. Martin A, Loenig K, Scahill L, Bregman J: Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 9:99-107, 1999.
40. Masi G, Cosenza A, Mucci M: Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharmacol 11:389-,394, 2001.
41. McCombs JS, Nichol MB, Stimmel GL, Shi J, Smith RR: Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. J Clin Psychiatry 60(Suppl 19):5-11, 1999.
42. McConville BJ, Arvanitis LA, Thyrum PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE: Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 61:252-260, 2000.
43. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ: Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label study. J Am Acad Child Adolesc Psychiatry 36:685-693, 1997.
44. McDougle CJ, Scahill L, McCracken JT, Aman MG, Tierney E, Arnold LE, Freeman BJ, Martin A, McGought JJ, Cronin P, Posey DJ, Riddle MA, Ritz L, Swiezy NB, Vitiello B, Volkmar FR, Volkmar FR, Votolato NA, Watson P: Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and ratione for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am 9:201-224, 2000.
45. Mozes T, Toren P, Chemauzan N, Mester R, Yoran-Hegesh R, Blumensohn R, Weizman A: Clozapine treatment in very early onset schizophrenia. J Am Acad Child Adolesc Psychiatry 33:65-70, 1994.
46. Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH: Long-term morbidity and mortality of overweight adolescents: A follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med 327:1350-1355, 1992.
47. Onofrj M, Paci C, D'Andreamatteo G, Toma L: Olanzapine in severe Gilles de la Tourette syndrome: A 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol 247:443-446, 2000.
48. Pappadopulos E, Jensen PS, Schur SB, MacIntyre JC, Ketner S, Van Orden K, Sverd J, Sardana S, Woodlock D, Schweitzer R, Rube D: "Real-world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophr Bull 28:111-121, 2002.
49. Parraga HC, Parraga MI, Woodward RL, Fenning PA: Quetiapine treatment with Tourette's syndrome: Report of two cases. J Child Adolesc Psychopharmacol 11: 187-191, 2001.
50. Perry R, Pataki C, Munoz-Silva DM, Armenteros J, Silva RR: Risperidone in children and adolescents with pervasive developmental disorder: Pilot trial and follow-up. J Child Adolesc Psychopharmacol 7:167-179, 1997.
51. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ: Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study. J Clin Psychopharmacol 19:37-44, 1999.
52. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, Philip M, Apter A, Weizman R: Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. J Am Acad Child Adolesc Psychiatry 41:337-343, 2002.
53. Remschmidt H, Schulz E, Martin M: An open trial of clozapine in thirty-six adolescents with schizophrenia. J Child Adolesc Psychopharmacol 4: 31-41, 1994.
54. Safer DJ: Changing patterns of psychotropic medications prescribed by child psychiatrists in the 1990s. J Child Adolesc Psychopharmacol 7:267-274, 1997.
55. Schreier HA: Risperidone for young children with mood disorders and aggressive behavior. J Child Adolesc Psychopharmacol 8:49-59, 1998.
56. Selva KA, Scott SM: Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr 138:936-938, 2001.
57. Soutullo CA, Sorter MT, Foster KD, McElroy SL, Keck PE: Olanzapine in the treatment of adolescent acute mania: A report of seven cases. J Affect Disord 53:279-283, 1999.
58. Van Itallie TB: Obesity: Adverse effects on health and longevity. Am J Clin Nutr 32:2723-2733, 1979.
59. Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J, Lenane MC, Rapoport JL: Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 9:239-245, 1999.
60. Zuddas A, Di Martino A, Muglia P, Cianchetti C: Long-term risperidone for pervasive developmental disorder: Efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 10: 79-90, 2000.